Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum

PRINCETON, N.J., Oct. 23 /PRNewswire/ -- Celator Pharmaceuticals today
announced that Scott Jackson, chief executive officer, is scheduled to present
at the BIO Investor Forum in San Francisco. Mr. Jackson will provide a
corporate overview and an update on the company's clinical development
programs. The presentation will be held on Wednesday, October 29, 2008 at
1:45 PM PDT in the Marina Room of the Palace Hotel.

The company is also pleased to announce that Dr. Arthur Louie, chief medical
officer, has been invited to participate in a therapeutic workshop titled,
"Pre-ASH Primer: Hematology Heavy Hitters Discuss What's on the Horizon." The
workshop will be held on Thursday, October 30, 2008 at 9:30 AM PDT in the Twin
Peak South Room of the Palace Hotel.

About Celator
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver,
BC, is a privately held pharmaceutical company developing new and more
effective therapies to treat cancer. CombiPlex(R), the company's drug ratio
technology platform, represents a revolutionary new approach to the
development of combination therapies based on identifying a fixed, synergistic
ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery
vehicle and maintaining the ratio in patients. The company pipeline includes:
CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a
Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal
formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in
patients with advanced leukemia; CPX-571 (a liposomal formulation of
irinotecan:cisplatin), a preclinical stage compound; and multiple research
programs. Based on the applications of CombiPlex, Celator is positioned to
advance a broad pipeline of combination therapies involving both previously
approved and novel drug agents. For more information, please visit the
company's website at www.celatorpharma.com.

SOURCE Celator Pharmaceuticals

Bill Berry of Berry & Company Public Relations, +1-212-253-8881,
bberry@berrypr.com